About hospital-acquired infections
Hospital-acquired diseases are also known as nosocomial infections that are acquired in hospitals and other healthcare facilities. These infections are classified only when a patient is admitted for reasons other than the infections and are caused by bacteria, fungi, parasites, or viruses. Most common types of hospital-acquired infections are SSIs, UTIs, bloodstream infections, pneumococcal infections, MRSA, and gastrointestinal illnesses. These infections appear between 48 hours and four days after a patient is admitted and are usually related to a treatment of procedure used to treat or diagnose the patient's initial illness or injury. Hospital-acquired diseases are preventable through adherence to strict guidelines and less usage of invasive equipment that must be followed by healthcare professionals while caring for the patient. Anti-infective drugs are used for the treatment of these infections. These infections can be minimized by following proper infection control measures in the hospitals and healthcare institutions.
Technavio's analysts forecast the global hospital infection therapeutics market to grow at a CAGR of 3.24% over the period 2014-2019.
Covered in this report
The report covers the present scenario and growth prospects of the global hospital infection therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of drugs used in the treatment of various hospital-acquired infections such as bloodstream infections, Clostridium difficile infections, hospital-acquired pneumonia, surgical site infections, and urinary tract infections.
Technavio's report, Global Hospital Infection Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global hospital infection therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key regions
• Americas
• APAC
• EMEA
Key vendors
• Allergan
• Bayer
• GlaxoSmithKline
• Merck
• Pfizer
Other prominent vendors
• Abbott Laboratories
• Achaogen
• AmpliPhi Biosciences
• Angelini Pharma
• Aridis Pharmaceuticals
• AstraZeneca
• Durata Therapeutics
• F. Hoffmann-La Roche
• Isis Pharmaceuticals
• Johnson & Johnson
• Ligand Pharmaceuticals
• Massachusetts Biological Laboratories
• Medarex
• Meiji Seika Pharma
• Melinta Therapeutics
• Nektar
• Novartis
• Prokarium
• Sanofi
• Tetraphase Pharmaceuticals
• The Medicines Company
• Valneva
Key market driver
• Development of multidrug resistant variants
• For a full, detailed list, view our report
Key market challenge
• Rise in number of infection control programs
• For a full, detailed list, view our report
Key market trend
• Patient assistance programs
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
Understanding disease
Modes of transmission
Types of infections
Prevention
Treatment
Epidemiology
Economic burden
PART 06: Pipeline analysis
PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 08: Market segmentation by drug class
Antibacterials
Antiviral drugs
Antifungal drugs
PART 09: Market segmentation by type of infections
Urinary tract infections
Respiratory tract infections
Bloodstream infections
Surgical site infections
Gastrointestinal infections
PART 10: Geographical segmentation
Segmentation of global hospital infection therapeutics market by geography
PART 11: Market drivers
Development of multidrug resistant variants
Rise in public health awareness
Special regulatory designation for pipeline molecules
Increase in number of surgical procedures
PART 12: Impact of drivers
Rise in number of infection control programs
Increased use of generics
Lack of proper healthcare infrastructure
PART 13: Market challenges
PART 14: Market trends
PART 15: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors
PART 16: Key vendor analysis
Allergan
Bayer HealthCare
GSK
Merck & Co
Pfizer
PART 17: Appendix
List of abbreviations
PART 18: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Types of contact transmission
Exhibit 03: Global hospital infection treatment market: Pipeline portfolio
Exhibit 04: Global hospital infection therapeutics market 2014-2019 ($ billions)
Exhibit 05: Five forces analysis
Exhibit 06: Global hospital infection therapeutics market segment by drug class
Exhibit 07: Types of antibacterial drug by chemical class
Exhibit 08: Types of antifungal drugs by chemical class
Exhibit 09: Global hospital infection therapeutics market segment by type of infections
Exhibit 10: Estimates of hospital-acquired infections occurring in acute care hospitals in the US 2011
Exhibit 11: Percentage share of market segment by type of infection 2014
Exhibit 12: Global hospital infection therapeutics market segment by geography 2014
Exhibit 13: Impact of drivers
Exhibit 14: Impact of drivers and challenges
Exhibit 15: Allergan: Key takeaways
Exhibit 16: Allergan: Year-over-year (YoY) growth and revenue generated from net sales of pharmaceutical products 2011-2014 ($ millions)
Exhibit 17: Allergan: YoY growth and revenue generated from net product sales of anti-infective 2011-2013 ($ millions)
Exhibit 18: Bayer: Key takeaways
Exhibit 19: GlaxoSmithKline: Key takeaways
Exhibit 20: GlaxoSmithKline: YoY growth and revenue generated from sales of Augmentin 2011-2014 ($ millions)
Exhibit 21: GlaxoSmithKline: Revenue generated from sales of Augmentin by region 2011-2014 ($ millions)
Exhibit 22: GlaxoSmithKline: YoY growth and revenue generated from sales of other antibacterial drugs 2013-2014 ($ millions)
Exhibit 23: Merck: Key takeaways
Exhibit 24: Merck: YoY growth and revenue generated from sales of Primaxin 2012-2014 ($ millions)
Exhibit 25: Merck: YoY growth and revenue generated from sales of Cancidas 2012-2014 ($ millions)
Exhibit 26: Merck: YoY growth and revenue generated from sales of Invanz 2012-2014 ($ millions)
Exhibit 27: Merck: YoY growth and revenue generated from sales of Noxafil 2012-2014 ($ millions)
Exhibit 28: Pfizer: Key takeaways
Exhibit 29: Pfizer: YoY growth and revenue generated from sales of Zyvox 2012-2014 ($ millions)
Exhibit 30: Pfizer: YoY growth and revenue generated from sales of Vfend 2012-2014 ($ millions)
Exhibit 31: Pfizer: YoY growth and revenue generated from sales of Zithromax and Zmax 2012-2014 ($ millions)
Exhibit 32: Pfizer: YoY growth and revenue generated from sales of Diflucan 2012-2014 ($ millions)
Exhibit 33: Pfizer: YoY growth and revenue generated from sales of Dalacin and Cleocin 2012-2014 ($ millions)
Exhibit 34: Allergan: Business segmentation 2014 by revenue
Exhibit 35: Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 36: Allergan: Geographical segmentation by revenue 2014
Exhibit 37: Geographical segmentation by revenue 2014
Exhibit 38: Business segmentation by total revenue 2013 and 2014 ($ billions)
Exhibit 39: Pfizer in pharmaceutical sector
Exhibit 40: Geographical segmentation by revenue 2014
